Observational studyEuropean journal of clinical pharmacology2019
Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling.
Observational study in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Self-Sampling by Adolescents at Home: Assessment of the Feasibility to Successfully Collect Blood Microsamples by Inexperienced Individuals.The AAPS journal · 2024Trial
- Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial.British journal of clinical pharmacology · 2020Trial
- Optimizing Dried Blood Spot Sampling for Children and Adolescents With Autism Spectrum Disorder.Therapeutic drug monitoring · 2026Article
- Dried blood spot-based monitoring of immune and epigenetic biomarkers in occupational exposure studies.Journal of exposure science & environmental epidemiology · 2026Article
- Patient centric blood sampling and analysis for diagnostics and laboratory medicine.Bioanalysis · 2025Review
- Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.Therapeutic drug monitoring · 2025Article
- Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital-Based Towards Home-Sampling.Biomedical chromatography : BMC · 2025Review
- Living Well: Protocol for a web-based program to improve quality of life in rural and urban ovarian cancer survivors.Contemporary clinical trials · 2024Article
- Remote dried blood spot collection for inflammatory markers in older adults is feasible, reliable, and valid.Brain, behavior, and immunity · 2024Article
- Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring.Journal of pharmaceutical analysis · 2024Review
- Citizens' perspectives on relocating care: a scoping review.BMC health services research · 2024Article
- Development and evaluation of serological screening based on one dried plasma spot for HIV, syphilis, and HCV.Virology journal · 2023Article
- Feasibility of remote self-collection of dried blood spots, hair, and nails among people with HIV with hazardous alcohol use.Alcohol, clinical & experimental research · 2023Article
- At-home dried blood spot (DBS) collection to increase population heterogeneity representation in pediatric research: An ECHO study.Frontiers in pediatrics · 2023Article
- Feasibility of community at-home dried blood spot collection combined with pooled reverse transcription PCR as a viable and convenient method for malaria epidemiology studies.Malaria journal · 2022Article
- Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples.Frontiers in oncology · 2022Review
- Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.European journal of clinical pharmacology · 2020Observational
- Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden.European journal of haematology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo obtain insight into the feasibility of, and the patients' perspective on, dried blood spot (DBS) self-sampling by patients with chronic myeloid leukemia (CML) using nilotinib.
methodsSixty-eight patients with CML using nilotinib participated in this multicenter observational study. Patients were asked to perform blood sampling by means of the DBS method at home just before drug intake (trough level) and to complete a questionnaire including demographics and five questions on their experience with DBS self-sampling.
resultsSixty-one patients (57.5 ± 15.0 years, 49% female) provided 178 DBS samples of which 137 (77%) proved useful in clinical practice. Twenty percent of the samples were rejected because the spot size was too small for analysis. A further 3% were taken at the wrong time. Unsuitable DBS samples were provided by 23 patients. Their educational level was significantly lower than that of patients whose samples were all suitable (p = 0.041). Patients considered DBS self-sampling easy and not painful, and three quarters of the patients performed DBS sampling without additional assistance. Patients' belief in the reliability of DBS self-sampling was moderate to high. It was preferred over venous sampling by 37% of the patients, whereas 39% had no preference.
conclusionDBS self-sampling by CML patients is feasible in clinical practice provided that patients, particularly those with a lower educational level, are adequately instructed about sample collection with emphasis on timing and volume of sample collection.
Indexed as
Identifiers
30729257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.